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Conclusions: ARA 290 protected pancreatic islets from cytokine-induced
damage and apoptosis in vitro and ameliorated the inflammatory response
following PITx. It appears to be a promising candidate for improvement of PITx.
Figure1: AUC in IPGTT is compared among na€ıve mouse, PITx with PBS
(control) and PITX with ARA290 (ARA 290). (*p < 0.05 versus control group;
values are depicted as lower quartile, median and upper quartile (boxes) with
minimum and maximum ranges.).
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Introduction: Islets grafting restores endogenous insulin production in Brittle
type 1 diabetic patients, but long-term outcomes remain disappointing due to
destruction of allogeneic islets by recipients’ adaptive immune system. In solid
organ transplantation, antibody-mediated rejection (AMR) is recognized as the
first cause of transplant failure. This experimental murine study aimed at
determining whether donor-specific antibodies (DSA) also contribute to islet
grafts destruction.
Methods and results: Diabetes was induced by streptozotocine injection in
RAG2 KO C57BL/6 (H-2b) mice, which lack T and B cells. Allogeneic (CBA, H-
2k) islets were not rejected by these immunocompromised recipients, which
remained euglycemic until the end of the follow-up (120 days). DSA (either
polyclonal immune sera or murine IgG2a anti H-2k mAb) were able to bind to
CBA islets and induce complement-dependent destruction b cell line in vitro. In
contrast, repeated IV injections of DSA did not impact CBA islet grafts function
in vivo. Live imaging studies, using radiolabelled DSA, showed that alloanti-
bodies were sequestrated in recipients’ vascular bed. As a consequence DSA
that were able to bind to allogeneic endothelium of CBA heart transplant, failed
to reach CBA islets. Indeed, while the vascularisation of transplanted organs
comes from the donor, graft vascularisation develops from recipient and is
therefore not allogeneic.
Conclusion: Our study demonstrates that, in contrast with solid organ
transplants, islet grafts are protected from humoral rejection due to vascular
sequestration of DSA.
BO276* ROLE OF BONE MARROW-DERIVED STEM CELLS,
RENAL PROGENATOR CELLS AND STEM CELL
FACTOR IN CHRONIC RENAL ALLOGRAFT
NEPHROPATHY
Hayam El Aggan1, Mona Salem1, Nahla Farahat1, Ahmad El-Koraie1, Ghaly
Kotb2
1Faculty of Medicine, University of Alexandria; 2Alexandria University Student
Hospital, University of Alexandria
Background: Bone marrow-derived stem cells (BMSCs) the hematopoietic
stem cells (HSCs) and mesenchymal stem cells (MSCs) are pluripotent cells
that can be mobilized into circulation and recruited to sites of inflammation. The
present work was designed to study circulating HSCs,MSCs and renal
progenitor cells (RPCs) and stem cell factor (SCF) in patients with chronic
allograft nephropathy (CAN) in relation to renal hemodynamics and histopatho-
logical changes.
Subjects: This study included 45 subjects, they were divided into three
groups each 15, renal transplant patients with stable renal function (Group I),
with CAN (Group II) and healthy subjects as controls (Group (III).
Methods: The HSCs and MSCs were identified as
CD34 + CD45 + CD117 + and CD34!CD45!CD106+ cells using flow
cytometry. Serum SCF levels were measured using enzyme linked immunosor-
bant assay kit. C-reactive protein (CRP),urinary alkaline phoshatase (U.ALP)
were measured. Immunohistochemical staining of renal biopsy was done using
monoclonal antibodies against CD133 for detection of CD133 + RPCs, CD34
for detection of CD34 + stem cells,vascular endothelial growth factor (VEGF)
as vascular marker and alpha smooth muscle actin (a-SMA) for renal fibrosis.
Renal hemodynamics was evaluated by duplex Doppler and resistive and
pulsatility indices (RI, PI) were calculated.
Results: There was a significant increase in the level of SCF,number
of HSCs,MSCs,RI and PI with a decrease of U. ALP in transplanted
patients than the controls. These were positively correlaed with each other
and with the markers of renal function. The renal CD133 + and CD34 + cells
were positively correlated with each other and with VEGF and negatively with
ASMA and fibrosis.
Conclusion: Renal transplantation is assocated with mobilization of BMSCs
from the BM into the circulation in parallel with an increased production of SCF
with severe kidney injury. The activation of endogenous RPCs may play a role
in limiting renal fibrosis and enhancing renal vasculature.
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Background/Aims: Acute kidney injury (AKI) remains a common clinical
problem with high mortality rates. Mesenchymal stem cells were so far shown
as a promising treatment option. It was recently reported that humanWharton’s
jelly derived mesenchymal stem cells (WJ-MSC) could ameliorate renal
function induced by low dose of cisplatin in rats. However, the role of WJ-
MSC in AKI induced with high nephrotoxic dosage cisplatin protocol (compa-
rable to human chemotherapeutic scheme) has not yet been demonstrated.
Therefore, we tested whether administration of multipotent WJ-MSC to mice
with cisplatin-induced AKI (17 mg/kg body weight intraperitoneally) could
improve kidney function and ameliorate damage in the kidney (the outcome
through amelioration of apoptosis and induction of tubular proliferative
response). The distribution of transplanted stem cells after peripheral infusion
was also assessed.
Methods: WJ-MSC were injected intravenously, 24 h after cisplatin applica-
tion. Cells were labeled with Dil for ex vivo tracing. At 96 h after cisplatin
induced AKI, serum creatinine and blood urea nitrogen were measured and
renal morphology analysis was assessed by histology to confirm the renopro-
tective effects of transplantedWJ-MSC. Tubular cell proliferation and apoptosis
were identified by immunostaining.
Results: After transplantation of WJ-MSC into mice with cisplatin-induced
AKI, improvements in renal function and recovery from tubular epithelial cell
injury were observed. Several cells engrafted in renal interstitium in the near
vicinity of injured tubular epithelia where they exposed their beneficial effects by
decreasing tubular cell apoptosis, with no markable effect on tubular cell
proliferation.
Conclusions: Infused WJ-MSC can reach damaged kidney tissue after
intravenous transplantation. AKI elicited by lethal dose of cisplatin was
considerably improved by WJ-MSC, in parallel with less apoptotic events, with
no influence on proliferative response.
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Background: Mesenchymal stromal cell (MSC) have immunomodulating
properties and could be used as immunosuppressive agents. We report the 6-
month safety results for the 5 first patients treated with MSC after kidney
transplantation (KTx). Here, we address 3 specific safety issues: immunization
against MSC and engraftment syndrome defined as acute graft dysfunction not
related to rejection and over-immunosuppression.
Patients andmethod: MSC production was carried out locally. MSCwere not
matched with kidney recipients’ HLA. Included patients were non-immunized,
first transplant recipients from deceased donors. MSC (1.5–3.0 9 106/kg)
infusion was planned 3 to 5 days post KTx. Patients with cardiovascular
instability post KTx were excluded. All patients were treated with Basiliximab
induction, Tacrolimus, Mycophenolate Mofetil and Steroid. We prospectively
screened for anti-HLA antibodies at month 1, 3 and 6. Informed consent was
obtained from all participants. The local ethical committee approved the
protocol.
Results: Collectively there were 23/50 and 29/50 HLA mismatches (MM) with
kidney and MSC donor respectively, out of which 5 were shared MM. One
patient developed de novo DSA, 2 patients anti-HLA antibodies against shared
kidney/MSC MM and 1 patient developed 2 specific antibodies against MSC
(MSCSA) at month 6. All antibodies were anti HLA class I except for 1. We did
not observe any “engraftment” syndrome. Three patients experienced non-
severe opportunistic infections: 1 CMV reactivation and 2 polyoma-BK virus
viremia.
Recipient Age at Tx (years) 63 ! 6
Gender (M/F) 4/1
BMI (kg/m2) 27 ! 3
Dialysis vintage (days) 373 ! 564
Kidney donor Age (years) 51 ! 18
Gender (M/F) 3/2
BMI (kg/m2) 26 ! 5
DBD/DCD 4/1
Transplantation CIT (min) 737 ! 219













Conclusion: We did not observe any strong safety signal. We did however
observe some degree of immunization in 3 patients: 2 developed antibodies
against shared kidney/MSC donor HLA MM and 1 MSCSA.
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Liver ischemia reperfusion injury (IRI) is inevitable during transplantation and
extended resections. Hepatic IRI is characterized by hepatocellular injury and
hepatocyte loss and may compromise regeneration. At present there is no
therapy to treat IRI. Therefore, potential therapeutic strategies to reduce
hepatic IRI and accelerate liver regeneration could offer major benefits in both
liver transplantation and resection. Mesenchymal stem cells (MSC) are
reported to have anti-inflammatory and regeneration promoting properties in
models of isolated ischemia or resection. Whether they are of benefit in a more
clinically relevant model where IRI is combined with resection induced need for
rapid regeneration is currently unknown. Therefore we investigated the effect of
MSC administration in a mouse model of combined IRI and partial resec-
tion. IRI was induced by occlusion of the blood flow to the left lateral and
median liver lobes for 60 min followed by partial hepatectomy of 40% of the
liver volume (PH) in C57Bl/6 mice. Animals were treated intravenously with 2-,
or 3 x105 mouse syngeneic MSC or PBS control, 2 h before-, or 1 h after IRI.
Six hours, and 2- and 5 days after combined ischemia and resection mice were
sacrificed. Liver damage was evaluated by measuring liver enzymes,
histological damage, and inflammatory markers IL-6 and TNF-a. Liver
regeneration was determined by measuring liver/body weight ratio and
numbers of proliferating hepatocytes at 2 and 5 days after combined IRI and
PH. Liver damage in mice treated with 3 x105 MSC was increased compared to
controls. 2 9 105 MSC 2 h before or 1 h after IRI and PH was not significantly
different from PBS treated control mice. Liver regeneration was also not
different from control animals. In contrast to what is generally assumed,
intravenous administration of high numbers of MSC increase liver damage,
whereas lower numbers have no beneficial effect on liver IRI or regeneration.
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Background: Ex vivo lung perfusion (EVLP) is a promising technique to
resuscitate potential donor lungs prior to transplantation. Clinical grade
multipotent adult progenitor cells (MAPCs) are a novel type of stem cells with
immunomodulatory properties. We report our first experience administrating
MAPCs during prolonged EVLP comparing intravascular (IV) and intratracheal
(IT) administration to modulate ischemia-reperfusion injury.
Materials and Methods: Porcine lungs were perfused for maximum 6 hrs on
EVLP following a warm ischemic interval of 90 min. Animals (n = 2/group)
were divided in 4 groups. In MAPC-IV group 10*106 MAPCs were adminis-
trated IV at onset of EVLP; in CONTR-IV group no cells were added to the
perfusate. In MAPC-IT group 10*106 MAPCs in 40 ml PBS were instilled in the
airways at onset of EVLP; in CONTR-IT group no cells were added to the PBS.
Functional evaluation included the % difference in PVR and Compliance
between end and onset of EVLP. Wet-to-dry weight (W/D) ratio was calculated.
Results: Data are depicted as mean.
Not all grafts could be perfused for 6 hrs due to massive edema. Therefore,
maximal perfusion time was documented. Decline in graft function was defined
as ↑PVR (+%PVR) or ↓compliance (-%COMPL). MAPCs IV further deteriorated
lung function and compromised perfusion time compared to CONTR-IV. In
contrast, it seems that lung function was better preserved in MAPC-IT
compared to CONTR-IT.
Conclusion: These preliminary data indicate that IT administration of MAPCs
during EVLP might offer a potential to resuscitate lung grafts. IV administration
of MAPCs led to deterioration of pulmonary function in this model. We
hypothesize that MAPCs IT might improve epithelial barrier function and
modulate the inflammatory response. More data are necessary to confirm
these findings and to elucidate potential mechanisms. Results will be updated
at time of presentation to n = 6/group.
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